What is established in thrombolytic therapy of acute myocardial infarction? Pharmacological approaches.
Thrombolytic therapy by early reopening of an occluded coronary vessel, and hence re-establishing oxygen delivery, can significantly reduce infarct size. The result depends both on the duration of ischemia and the presence of collaterals. By early initiation of intravenous thrombolytic therapy and shortening the ischemic period, the functional results may be improved. PTCA has to be considered in order to avoid reocclusion of the infarct vessel, mainly in patients with high-grade residual stenosis and viable myocardium in the poststenotic area. The benefit of early thrombolytic therapy in acute myocardial infarction has been proven in randomized trials. However, to achieve statistical significance, a large number of patients had to be included. It is mainly the patients with previous myocardial infarction with a large area at infarct risk and/or anterior myocardial infarction that derive most benefit from this intervention.
Kübler
W
W
Medizinische Klinik III (Kardiologie), Universität Heidelberg, West Germany.
Bode
C
C
Schömig
A
A
Schuler
G
G
Schwarz
F
F
D000208:Acute Disease; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology
D005343:Fibrinolytic Agents